Warning: You're using a guest account.
Unless you register as a full user all information associated with this session will be deleted within 24 hours.
GS3649 • Candidate genes for bipolar and related disorders-Differentially expressed in mouse brain in response to Methamphetamine or Valproate
Genes reproducibly changed by Methamphetamine and/or Valproate treatment in mouse brain including PreFrontal Cortex, Amygdala, CaudatePutamen, Nucleus Accumbens and Ventral Tegmentum. (Tables 1-3 of paper)
Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, Kuczenski R, Niculescu AB
Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach.
Vol 9, pp. 1007-29
Identifying genes for bipolar mood disorders through classic genetics has proven difficult. Here, we present a comprehensive convergent approach that translationally integrates brain gene expression data from a relevant pharmacogenomic mouse model (involving treatments with a stimulant--methamphetamine, and a mood stabilizer--valproate), with human data (linkage loci from human genetic studies, changes in postmortem brains from patients), as a bayesian strategy of crossvalidating findings. Topping the list of candidate genes, we have DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) located at 17q12, PENK (preproenkephalin) located at 8q12.1, and TAC1 (tachykinin 1, substance P) located at 7q21.3. These data suggest that more primitive molecular mechanisms involved in pleasure and pain may have been recruited by evolution to play a role in higher mental functions such as mood. The analysis also revealed other high-probability candidates genes (neurogenesis, neurotrophic, neurotransmitter, signal transduction, circadian, synaptic, and myelin related), pathways and mechanisms of likely importance in pathophysiology.
PUBMED: 15314610 Find other GeneSets from this publication